Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00164723
Other study ID # CE_GIB
Secondary ID
Status Completed
Phase N/A
First received September 9, 2005
Last updated August 10, 2015
Start date February 2005
Est. completion date November 2014

Study information

Verified date January 2011
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Department of Health
Study type Interventional

Clinical Trial Summary

To evaluate the incidence and etiology of small bowel or large bowel bleeding in patients presenting with melena.


Description:

Although tarry stool is a common feature of peptic ulcer bleeding, it can also be a manifestation of lower gastrointestinal (GI) bleeding. Examples include colonic cancer, small bowel tumors, and small or large bowel ulcers induced by aspirin or painkillers (NSAIDs). However, clinicians are often misled by the finding of peptic ulcers as the source of GI bleeding. It is not uncommon to detect peptic ulcers incidentally but the source of bleeding is actually in the lower GI tract (e.g. NSAID- or aspirin-induced small or large bowel bleeding ulcers, small bowel tumors, or colorectal cancer). Delay in diagnosis of lower GI bleeding often leads to serious consequences.

The preferred investigations for lower GI bleeding are colonoscopy plus video capsule endoscopy. Colonoscopy has been the gold standard for the diagnosis of colonic bleeding. The risk of colonoscopy-induced complications such as bleeding or perforation is less than 1 in 3500. Video capsule endoscopy is a non-invasive, safe and accurate technology that has been approved by the FDA for investigation of small bowel diseases. The video capsule is an 11x 26mm capsule that encases a digital camera, light-emitting diodes, batteries, and a transmitter. The patient needs to swallow the video capsule after an overnight fast and wear a recording device for eight hours. Images are taken twice-per-second and transmitted to the recording device. Oral feeding can be resumed after four hours. There is no restriction to daily activities. The swallowed capsule will be expelled naturally after 5 to 12 hours virtually in all patients. The risk of capsule retention is very low and only occurs in patients with severe small bowel stricture.

This study aims to assess the incidence and etiology of lower GI bleeding in patients presenting with tarry stool. The result will provide important information about the magnitude of the problem of lower GI bleeding that will improve our patient care.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Consecutive patients with a clinical diagnosis of upper gastrointestinal bleeding will be enrolled if they meet all of the following criteria:

1. Presence of melena or melena concomitant with PR bleeding;

2. Gastroscopic findings not accountable for the upper GI bleeding including: (i) clean base ulcers /erosions (refer to User Groups below) without high-risk stigmata, fresh or altered blood but can have grade A or B esophagitis concomitantly ; and (ii) meet the criteria of either the User groups or Non-user group as below

User Groups Definition: Patients who used any dose of NSAIDs or aspirin via oral or systemic (intramuscular, Per rectal) route within 2 weeks prior to the onset of upper GI bleeding NSAID group: Clean base gastric or duodenal ulcer is required (i.e., patients with normal finding or erosions alone on endoscopy will not be eligible) Aspirin group: Either an ulcer or multiple (>5) erosions found on endoscopy

Non-user group

Definition :

1. No continuous use of NSAIDs or aspirin for more than 1 week within the past 3 Months and patients who had not been exposed to NSAIDs, aspirin, or unknown drugs = 4 weeks prior to GI bleed;

2. Clean base gastric or duodenal ulcer is required (i.e., patients with normal finding or erosions alone on OGD will not be eligible)

3. Age ³18;

4. Willing to meet the capsule endoscopy procedure requirements, and have provided written informed consent prior to admission to this study.

5. Concomitant clean base GU and DU can be recruited

Exclusion criteria

The presence of any of the following will exclude a subject from study enrollment:

1. Hematemesis as the presenting symptom;

2. Gastroscopic findings accountable for the bleeding episode (i.e., presence of blood in the stomach, ulcers showing high-risk bleeding stigmata, bleeding gastroesophageal varices, Mallory-Weiss tear showing bleeding stigmata, portohypertensive gastropathy);

3. Gastroscopic findings are normal.

4. Uncontrolled bleeding requiring emergency surgery or mesenteric angiography;

5. Has cardiac pacemaker or other electromedical implant;

6. Is expected to undergo MRI examination or be in the vicinity of powerful electromagnetic fields between ingesting the capsule and its excretion;

7. Active malignancy or history of a malignancy within 5 years prior to enrollment;

8. Previous gastric surgery;

9. Known or suspected complete or partial stenosis of the small intestine;

10. Established delayed gastric emptying or diabetic gastroparesis;

11. Known inflammatory bowel disease;

12. Use of misoprostol within the 2 weeks prior to admission;

13. Concomitant use of NSAIDs and aspirin;

14. Currently taking anticoagulants or lithium;

15. Has a swallowing disorder that precludes safe ingestion of the capsule;

16. Pregnancy;

17. History of clinically significant substance abuse, drug addiction or a history of chronic ingestion of more than two alcoholic drinks per day;

18. Any mental or physical condition, which precludes compliance with study and/or device instructions;

19. Received any investigational medication within 30 days prior to the treatment period;

20. Currently participating in another clinical study that may affect the results of this study.

21. Ulcer > 2cm

22. clean base ulcer with grade C or D esophagitis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
Capsule endoscopy
Capsule endoscopy and colonoscopy

Locations

Country Name City State
China Endoscopy Center in Prince of Wales Hospital Hong Kong (SAR)

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic yield of capsule endoscopy as the primary investigation for small bowel after negative esophagogastroduodenoscopy 48 hours Yes
See also
  Status Clinical Trial Phase
Completed NCT02903017 - Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage Phase 4
Recruiting NCT02514304 - Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT01477320 - Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. N/A
Not yet recruiting NCT01549418 - The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Phase 4
Completed NCT02105532 - Transfusion in Gastrointestinal Bleeding Phase 2/Phase 3
Recruiting NCT05226221 - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Active, not recruiting NCT02874326 - Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Phase 2
Completed NCT02928939 - Therapeutic Conflicts and Multimorbidity
Withdrawn NCT01215058 - Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer N/A
Completed NCT01029626 - Glasgow-Blatschford Score Validation in Digestive Hemorrhage N/A
Completed NCT00251979 - A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer Phase 3
Completed NCT02991612 - Rifaximin in Patients With Gastroesophageal Variceal Bleeding N/A
Recruiting NCT02964195 - Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding N/A
Terminated NCT02609100 - Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy N/A
Completed NCT02965209 - European Novel Motorized Spiral Endoscopy Trial N/A
Completed NCT02349490 - Seraseal for Endoscopic Hemostasis Phase 4
Completed NCT01872286 - Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2 N/A
Withdrawn NCT01005147 - Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding N/A
Completed NCT00570973 - Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy Phase 4